Cashu
Biogen's Industry Response: JNJ Invests $2 Billion in U.S. Manufacturing Amid Regulatory Changes
3 days ago
Stocks
Health Care
biib
Biogen
NASDAQ: BIIB
-0.43 (-0.31%)
136.29
USD
At close at Aug 27, 20:33 UTC
Overview
Loading chart...
Key Stats
Market Cap
20.03B
Dividend Yield
0.00%
P/E Ratio
13.09
EPS
11.22
Revenue
9.68B
Avg. Volume
1.20M
About
What does BIIB do?
Biogen, headquartered in Cambridge, Massachusetts, specializes in therapies for neurological diseases, employing 7,570 people and offering treatments for conditions like MS, SMA, Alzheimer's, and ALS. Their product portfolio includes TECFIDERA, SPINRAZA, and collaborations on LEQEMBI and others.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.